- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04952571
Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)
An Exploratory Study on Camrelizumab Combined With Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There is no effective chemotherapy regimen for recurrent glioblastoma. The antiangiogenic drug bevacizumab has high objective response rate and rapid onset, but the duration of efficacy needs to be improved.The objective response rate of PD-1 monoclonal antibody immunotherapy is low and the onset of the effect is slow, but the effective patients have a long duration of efficacy.The combined treatment of PD-1 monoclonal antibody and bevacizumab may learn from each other to improve the effective rate, shorten the onset time and prolong the duration of efficacy.Studies have shown that bevacizumab can enhance the efficacy of immunotherapy in a variety of cancers, including melanoma, kidney cancer, non-small cell lung cancer, and liver cancer.However, previous studies have shown limited efficacy of PD-1 monoclonal antibody combined with bevacizumab in the treatment of recurrent glioblastoma.
In this study, the combination therapy was optimized by introducing induction phase therapy, which is expected to further improve the efficacy. In our previous exploratory treatment of patients with severe recurrent glioblastoma after multiple treatments, the initial efficacy was considerable.
The purpose of this study is to evaluate the efficacy and safety of camrelizumab [a programmed cell death 1 (PD-1) inhibitor] combined with bevacizumab for adult patients with recurrent glioblastoma.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jun-ping Zhang, MD
- Phone Number: 86-010-62856783
- Email: doczhjp@hotmail.com
Study Locations
-
-
-
Beijing, China
- Beijing Sanbo Brain Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18~70, male or female
- Primary supratentorial glioblastoma with first or second rogression/recurrence
- IDH1/2 wildtype
- KPS score ≥70 in patients with the first recurrence and ≥60 in patients with the second recurrence
- Expected survival ≥12 weeks.
- The time interval from the last radiotherapy was ≥12 weeks, unless there was new tumor enhancement in the radiological field or clear evidence of tumor hipathology.
- Radiotherapy and at least one regimen of chemotherapy before recurrence (excluding temozolomide chemotherapy during concurrent radiotherapy).
- The patients were enrolled after the end of the previous chemotherapy interval and had recovered from the related adverse reactions (except hair loss and pigmentation).
- The tumor was confirmed to have definite recurrence by MRI, with enhanced lesion diameter ≥1cm and ≥2 layers (layer spacing 5mm), or was confirmed to have recurrence by pathology after re-biopsy or surgery.
- The time interval between the last operation and the last biopsy was ≥4 weeks or ≥2 weeks at the time of enrollment.
- The main organs function normally, no serious abnormal blood, heart, lung, liver, kidney function and immune deficiency diseases
- Women of childbearing age are required to have a negative pregnancy test (serum or urine) within 7 days before enrolment and to voluntarily use contraception during treatment and within 8 weeks after the last treatment;For men, they should be surgically sterilized or agree to use contraception during treatment and for 8 weeks after the last treatment.
- Patients voluntarily enrolled in this study and signed informed consent (ICF).
- Good compliance is expected, efficacy and adverse reactions can be followed up according to protocol requirements
Exclusion Criteria:
- Glioblastoma in the midline (thalamus, brainstem, sellar region, etc.).
- Patients with initial recurrence had previously received long-term high-dose antiangiogenic drugs (except those with amlotinib or apatinib for less than 1 month and no progress during treatment, except those with intermittent bev dose intensity ≤5mg/ week and ≤3 times) or immunocheckpoint inhibitors, TCR-T, CAR-T, etc.;Patients with secondary recurrence had previously received long-term high-dose therapy of Bev (except for intermittent Bev dose intensity ≤5mg/ week and ≤3 times) or immunocheckpoint inhibitors, TCR-T, or CAR-T.
- Other study drugs are being used.
- An allergic reaction or intolerance to any component of the drug used in this study is known.
- Other malignant tumors in the past 3 years.
- Subjects who had been systematically treated with corticosteroids (>4mg/day dexamethasone or other equivalent hormone) or other immunosuppressants within 2 weeks prior to first use of carrelizumab.In the absence of active autoimmune disease, inhaled or topical corticosteroids and hormone replacement therapy with doses less than or equal to 4mg/ day of dexamethasone are permitted.
- The presence or history of any active autoimmune disease .
- Uncontrolled hypertension.
- Myocardial infarction occurred within 6 months prior to enrollment, New York Heart Society Class II heart failure or above, uncontrolled angina pectoris, uncontrolled severe arrhythmias, clinically significant pericardial disease, and electrocardiogram indicating acute ischemia or abnormal active conduction system.
- Abnormal coagulation function, bleeding tendency or receiving thrombolytic or anticoagulant therapy.
- Before entering the study 3 months there have been significant clinical significance of bleeding symptoms or have definite bleeding tendency;Or arterial/venous thrombosis events, such as cerebrovascular accidents, deep vein thrombosis and pulmonary embolism, occurred within 6 months before the study.
- Severe infection occurred within 4 weeks prior to initial administration;Or unexplained fever >38.5℃ during screening/prior to first administration.
- People who have a history of abuse of psychotropic substances and are unable to get rid of them or have mental disorders.
- Had major surgery or had an open wound or fracture within 4 weeks prior to first administration.
- Empty sinus passages or perforations were observed within 6 months prior to study entry.
- Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), active hepatitis B (HBVDNA≥500IU/ mL), hepatitis C (positive hepatitis C antibody and HCV-RNA above the detection limit of the assay method) or co-infection with hepatitis B and hepatitis C.
- Patients who received anti-tumor vaccine or other immunomodulatory drugs within 4 weeks before enrolment;Patients who have received or will receive live attenuated or recombinant vaccine within 4 weeks;Patients who received or will receive the inactivated vaccine within 1 week.
- Pregnancy and lactation.
- Other conditions that the investigator considered inappropriate for inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GBM at first relapse
|
Stage 1: Targeted therapy induction phase: bevacizumab 5mg/kg, intravenous infusion, once every two weeks, 2 cycles in total. Phase 2: Targeted combined immunotherapy: once every three weeks with the following drugs: (1) bevacizumab 7.5mg/kg intravenously;(2) Carrelizumab: 200mg/ time, intravenous infusion. |
Experimental: GBM at second relapse
|
Stage 1: Targeted therapy induction phase: bevacizumab 5mg/kg, intravenous infusion, once every two weeks, 2 cycles in total. Phase 2: Targeted combined immunotherapy: once every three weeks with the following drugs: (1) bevacizumab 7.5mg/kg intravenously;(2) Carrelizumab: 200mg/ time, intravenous infusion. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival rate at 6 months
Time Frame: Up to three years
|
Progression-free survival rate at 6 months
|
Up to three years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS(overall survival)
Time Frame: Up to three years
|
the time interval from entry to death from any cause or last follow-up and is measured in the intent-to-treat population
|
Up to three years
|
PFS(progression free survival)
Time Frame: Up to three years
|
the time interval from entry to tumor progression, death from any cause, or last follow-up
|
Up to three years
|
ORR(objective response rate)
Time Frame: Up to three years
|
rate of CR+PR
|
Up to three years
|
DCR(Disease Control Rate)
Time Frame: Up to three years
|
rate of CR+PR+SD
|
Up to three years
|
The correlation between KPS change and efficacy
Time Frame: Up to three years
|
the correlation between KPS baseline, KPS change (increase, decrease,stable) and best efficacy (CR, PR, SD, PD).
|
Up to three years
|
Median duration of KPS ≥ 70
Time Frame: Up to three years
|
Median duration of KPS ≥ 70 during progression-free survival
|
Up to three years
|
Frequency and severity of treatment-related adverse events
Time Frame: Up to three years
|
Frequency and severity of treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
|
Up to three years
|
Median duration of stable/improved quality of life assessed by EORTC QLQ-C30
Time Frame: Up to three years
|
the time interval from entry to change of ≥10 points on the EORTC QLQ-C30 without further improvement or disease progression or death.
|
Up to three years
|
Median duration of stable/improved quality of life assessed by EORTC QLQ-BN20
Time Frame: Up to three years
|
the time interval from entry to change of ≥10 points on the EORTC QLQ-BN20 without further improvement or disease progression or death.
|
Up to three years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Recurrence
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
- OBU-BJ-GBM-II-007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Glioblastoma
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); University of California, Los Angeles; Oncoceutics...WithdrawnRecurrent Glioblastoma | Recurrent Gliosarcoma | Recurrent Supratentorial Glioblastoma | Supratentorial GliosarcomaUnited States
-
Massachusetts General HospitalNot yet recruitingGlioblastoma Recurrent, EGFR vIII Mutant | Newly Diagnosed Glioblastoma, EGFRvIII Mutant | Recurrent Glioblastoma, EGFR vIII NegativeUnited States
-
National Cancer Institute (NCI)SuspendedRecurrent Glioblastoma, IDH-Wildtype | MGMT-Methylated Glioblastoma | Recurrent MGMT-Methylated GlioblastomaUnited States
-
University of OklahomaGlaxoSmithKlineTerminatedRecurrent Glioblastoma | Recurrent Glioma | Recurrent Astrocytoma | Recurrent OligodendrogliomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Glioblastoma | Giant Cell Glioblastoma | Recurrent GliosarcomaUnited States
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Newly Diagnosed Glioblastoma | Recurrent Gliosarcoma | Recurrent Astrocytoma, Grade IV | Newly Diagnosed Gliosarcoma | Newly Diagnosed Astrocytoma, Grade IVUnited States
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Center for Neurosciences, TucsonGenentech, Inc.CompletedRecurrent Glioblastoma Multiforme | Recurrent GliosarcomaUnited States
-
Jonsson Comprehensive Cancer CenterBristol-Myers Squibb; Northwest Biotherapeutics; Brain Tumor Funders CollaborativeWithdrawnGliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Small Cell Glioblastoma | Giant Cell GlioblastomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; Lantheus Medical Imaging; CarTheraRecruitingGlioblastoma | Glioblastoma Multiforme | Gliosarcoma | GBM | Recurrent Glioblastoma | Glioblastoma, IDH-wildtypeUnited States
Clinical Trials on Camrelizumab and Bevacizumab
-
Fudan UniversityNot yet recruitingMetastatic Liver CancerChina
-
The First Affiliated Hospital of Zhengzhou UniversityNot yet recruitingMalignant Pleural Effusion
-
Shandong Provincial HospitalUnknown
-
Zhejiang Cancer HospitalUnknown
-
Fudan UniversityRecruiting
-
Henan Provincial People's HospitalNot yet recruiting
-
Huashan HospitalJiangsu HengRui Medicine Co., Ltd.; Shanghai Sunstem Biotechnology Co., Ltd.RecruitingRecurrent GlioblastomaChina
-
Zhejiang Cancer HospitalNot yet recruitingUterine Cervical Neoplasms | Oncolytic Virotherapy | CamrelizumabChina
-
The First Affiliated Hospital of Zhengzhou UniversityRecruitingEsophageal Cancer by AJCC V8 StageChina
-
Peking UniversityNot yet recruiting